Evidence map›Paper›PMID 37466803›Full record

ArticleCell regeneration (London, England)2023

Chemical screening links disulfiram with cardiac protection after ischemic injury.

Yuanyuan Chen, Jianyong Du, Lixia Zheng, Zihao Wang, Zongwang Zhang, Zhengyuan Wu, Xiaojun Zhu, Jing-Wei Xiong

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell regeneration (London, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. The Yin and Yang of copper in cardiovascular health and disease.Molecular and cellular biochemistry · 2026
    Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Yuanyuan ChenBeijing Key Laboratory of Cardiometabolic Molecular Medicine, Institute of Molecular Medicine, College of Future Technology, and State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing, 100871, China.
Jianyong DuSchool of Health and Life Sciences, University of Health and Rehabilitation Sciences, Qingdao, 266071, China.
Lixia ZhengBeijing Key Laboratory of Cardiometabolic Molecular Medicine, Institute of Molecular Medicine, College of Future Technology, and State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing, 100871, China.
Zihao WangBeijing Key Laboratory of Cardiometabolic Molecular Medicine, Institute of Molecular Medicine, College of Future Technology, and State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing, 100871, China.
Zongwang ZhangBeijing Key Laboratory of Cardiometabolic Molecular Medicine, Institute of Molecular Medicine, College of Future Technology, and State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing, 100871, China.
Zhengyuan WuPKU-Nanjing Institute of Translational Medicine, Nanjing, 211800, China.
Xiaojun ZhuBeijing Key Laboratory of Cardiometabolic Molecular Medicine, Institute of Molecular Medicine, College of Future Technology, and State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing, 100871, China.
Jing-Wei XiongBeijing Key Laboratory of Cardiometabolic Molecular Medicine, Institute of Molecular Medicine, College of Future Technology, and State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing, 100871, China. jingwei_xiong@pku.edu.cn.ORCID http://orcid.org/0000-0001-8438-4782
Peking University · CN

Funding

National Key R&D Program of China 2018YFA0800501National Key R&D Program of China 2019YFA0801602National Natural Science Foundation of China 31430059National Natural Science Foundation of China 31730061National Natural Science Foundation of China 32230032National Natural Science Foundation of China 81870198Natural Science Foundation of Shandong Province ZR2022QH394
6 · The paper itself

Abstract

Ischemia-reperfusion injury occurs after reperfusion treatment for patients suffering myocardial infarction, however the underlying mechanisms are incompletely understood and effective pharmacological interventions are limited. Here, we report the identification and characterization of the FDA-approved drug disulfiram (DSF) as a cardioprotective compound. By applying high-throughput chemical screening, we found that DSF decreased H

Indexed as

DisulfiramGasdermin DHigh-throughput chemical screeningIschemia/reperfusion injuryRat cardiomyocytesSmall molecule

Identifiers

PMID37466803
PMCPMC10356704
OpenAlexW4384664738

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.